stockrowEli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company (LLY) Revenue growth
Eli Lilly and Company's revenue growth over the twelve months to 30 September 2026 was 45.5%, up 0.8 percentage points from fiscal 2025 (44.7%). Over the past ten years it has ranged from −5.88% (fiscal 2017) to 44.7% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 6.72% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 44.7% | 12.70 |
| FY2024 | 32.0% | 12.44 |
| FY2023 | 19.6% | 18.77 |
| FY2022 | 0.79% | (14.61) |
| FY2021 | 15.4% | 5.45 |
| FY2020 | 9.95% | 6.11 |
| FY2019 | 3.84% | (3.77) |
| FY2018 | 7.61% | 13.49 |
| FY2017 | −5.88% | (12.21) |
| FY2016 | 6.33% | 4.58 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 38.6% | (9.06) |
| Jun 2026 | 47.7% | (7.87) |
| Mar 2026 | 55.5% | 12.99 |
| Dec 2025 | 42.6% | (11.32) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| LLY Eli Lilly and Company | 45.5% |
| ABBV AbbVie Inc. compare | 10.7% |
| AMGN Amgen Inc. compare | 8.15% |
| JNJ Johnson & Johnson compare | 7.80% |
| AZN AstraZeneca PLC compare | 7.32% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| MRK Merck & Co., Inc. compare | 4.89% |
| NVS Novartis AG compare | 1.76% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement